Identification of an immunogenic CD8+ T-cell epitope derived from γ-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia

Blood

Volumn 108, Issue 8, 2006, Pages 2662-2668

  Hirano, Naoto ^a   Butler, Marcus O ^b   Xia, Zhinan ^b   Berezovskaya, Alla ^b   Murray, Andrew P ^b   Ansén, Sascha ^b   Kojima, Seiji ^b   Nadler, Lee M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA GLOBIN; LEUKOCYTE ANTIGEN; TUMOR ANTIGEN; GLOBIN; HLA A2 ANTIGEN;

AMINO ACID SEQUENCE; ARTICLE; CD8+ T LYMPHOCYTE; CELL SURFACE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; JUVENILE MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL; ANTIGEN PRESENTING CELL; CHILD; GENETICS; IMMUNOLOGY; IN VITRO STUDY; ISOLATION AND PURIFICATION; METABOLISM; MYELOMONOCYTIC LEUKEMIA;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CHILD; EPITOPES; GLOBINS; HLA-A2 ANTIGEN; HUMANS; LEUKEMIA, MYELOMONOCYTIC, ACUTE;

EID: 33749324960     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-04-017566     Document Type: Article

References (39)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147-1157.
2. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004;113:1515-1525.
3. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3:630-641.
4. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103:767-776.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
6. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
7. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
8. Hirano N, Butler MO, Xia Z, et al. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood. 2006;107:1528-1536.
9. Hirano N, Butler MO, Xia Z, et al. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res. 2006;12:2967-2975.
10. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood. 1997;90:479-488.
11. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277-282.
12. Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 1997;89:3534-3543.
13. Novitzky N. Myelodysplastic syndromes in children: a critical review of the clinical manifestations and management. Am J Hematol. 2000;63:212-222.
14. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105:410-419.
15. Manabe A, Okamura J, Yumura-Yagi K, et al. Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMMLWorking Group. Leukemia. 2002;16:645-649.
16. Pulsipher MA, Adams RH, Asch J, Petersen FB. Successful treatment of JMML relapsed after unrelated allogeneic transplant with cytoreduction followed by DLI and interferon-alpha: evidence for a graft-versus-leukemia effect in nonmonosomy-7 JMML. Bone Marrow Transplant. 2004;33:113-115.
17. Worth A, Rao K, Webb D, Chessells J, Passmore J, Veys P. Successful treatment of juvenile myelomonocytic leukemia relapsing after stem cell transplantation using donor lymphocyte infusion. Blood. 2003;101:1713-1714.
18. Yoshimi A, Bader P, Matthes-Martin S, et al. Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia. Leukemia. 2005;19:971-977.
19. Privitera E, Schiro R, Longoni D, et al. Constitutive expression of GATA-1, EPOR, alpha-globin, and gamma-globin genes in myeloid clonogenic cells from juvenile chronic myelocytic leukemia. Blood. 1995;86:323-328.
20. Hirano N, Butler MO, Von Bergwelt-Baildon MS, et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003;102:4567-4575.
21. Hirano N, Takahashi T, Ohtake S, et al. Expression of costimulatory molecules in human leukemias. Leukemia. 1996;10:1168-1176.
22. Craiu A, Akopian T, Goldberg A, Rock KL. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc Natl Acad Sci U S A. 1997;94:10850-10855.
23. Mo XY, Cascio P, Lemerise K, Goldberg AL, Rock K. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J Immunol. 1999;163:5851-5859.
24. Stoltze L, Dick TP, Deeg M, Pommerl B, Rammensee HG, Schild H. Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities. Eur J Immunol. 1998;28:4029-4036.
25. Hernandez J, Garcia-Pons F, Lone YC, et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLAA2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A. 2002;99:12275-12280.
26. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000;97:4796-4801.
27. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10:673-679.
28. Ayyoub M, Migliaccio M, Guillaume P, et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol. 2001;31:2642-2651.
29. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res. 2004;10:4688-4698.
30. Speiser DE, Cerottini JC, Romero P. Can hTERT peptide (540-548)-specific CD8 T cells recognize and kill tumor cells? Cancer Immun. 2002;2:14.
31. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.
32. Altman AJ, Palmer CG, Baehner RL. Juvenile "chronic granulocytic" leukemia: a panmyelopathy with prominent monocytic involvement and circulating monocyte colony-forming cells. Blood. 1974;43:341-350.
33. Amenomori T, Tomonaga M, Yoshida Y, et al. Cytogenetic evidence for partially committed myeloid progenitor cell origin of chronic myelomonocytic leukaemia and juvenile chronic myeloid leukaemia: both granulocyte-macrophage precursors and erythroid precursors carry identical marker chromosome. Br J Haematol. 1986;64:539-546.
34. Inoue S, Shibata T, Ravindranath Y, Gohle N. Clonal origin of erythroid cells in juvenile chronic myelogenous leukemia. Blood. 1987;69:975-976.
35. Mark Z, Toren A, Amariglio N, Vonsover A, Rechavi G, Brok-Simoni F. Rearrangement of the immunoglobulin heavy chain gene in juvenile chronic myeloid leukaemia. Br J Haematol. 1995;90:353-357.
36. Nakamura Y, Ito M, Yamamoto T, et al. Engraftment of NOD/SCID/ gammac(null) mice with multilineage neoplastic cells from patients with juvenile myelomonocytic leukaemia. Br J Haematol. 2005;130:51-57.
37. Storkus WJ, Zeh HJ 3rd, Maeurer MJ, Salter RD, Lotze MT. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol. 1993;151:3719-3727.
38. Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004;10:828-839.
39. Schreurs MW, Kueter EW, Scholten KB, Kramer D, Meijer CJ, Hooijberg E. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope. Cancer Immunol Immunother. 2005;54:703-712.